The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| BIOX | -73.06% | -68.11% | -20.43% | -64% |
| S&P | +18.54% | +92.9% | +14.04% | +140% |
Bioceres Crop Solutions Corp. engages in the provision of crop productivity solutions. The firm includes seeds, seed traits, seed treatments, biologicals, high-value adjuvants and fertilizers. It operates through the following segments: Seed and Integrated Products, Crop Protection, and Crop Nutrition. The Seed and Integrated Products segment deals with the development and commercialization of integrated products that combine three complementary components biotechnological events, germplasm and seed treatments in order to increase crop productivity and create value for customers. The Crop Protection segment develops and produces adjuvants, insecticides and fungicides. The Crop Nutrition segment focuses on the development, production and commercialization of inoculants that allow the biological fixation of nitrogen in the crops and of fertilizers including bio fertilizers and micro granulated fertilizers that increases the productivity and yield of the crops. The company was founded on November 14, 2017 and is headquartered in Rosario, Argentina.
No news articles found for Bioceres Crop Solutions.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $74.40M | -40.2% |
| Gross Profit | $25.10M | -39.7% |
| Gross Margin | 33.74% | 0.3% |
| Market Cap | $280.32M | -60.2% |
| Market Cap / Employee | $0.29M | 0.0% |
| Employees | 983 | 0.0% |
| Net Income | -$48.00M | -2206.9% |
| EBITDA | -$0.17M | -101.0% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q1 2025 | YOY Change | |
|---|---|---|
| Net Cash | $38.46M | 135.0% |
| Accounts Receivable | $187.51M | -11.2% |
| Inventory | 99.9 | -27.5% |
| Q1 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $95.88M | -18.9% |
| Short Term Debt | $186.71M | 27.8% |
| Q1 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -1.11% | -1.5% |
| Return On Invested Capital | 0.03% | 4.5% |
| Q1 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $20.20M | 185.1% |
| Operating Free Cash Flow | $21.48M | 197.5% |
| Metric | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 259.43 | 221.10 | 349.78 | 264.35 | 584.26% |
| Price to Book | 1.54 | 1.23 | 0.92 | 0.90 | -59.66% |
| Price to Sales | 1.12 | 0.94 | 0.75 | 0.85 | -42.01% |
| Price to Tangible Book Value | 23.04 | 30.04 | 23.31 | 52.00 | 33.61% |
| Price to Free Cash Flow TTM | 94.30 | 7765.12 | 19.71 | - | |
| Enterprise Value to EBITDA | 56.89 | 97.29 | 52.68 | -3245.36 | -5046.68% |
| Free Cash Flow Yield | 1.1% | 0.0% | 5.1% | - | |
| Return on Equity | 1.1% | 0.5% | 0.5% | -3.0% | -391.86% |
| Total Debt | $280.23M | $275.92M | $294.93M | $282.59M | 6.89% |
No podcast episodes available.
BIOX earnings call for the period ending June 30, 2022.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
